logo
FTC Approves Omnicom-IPG Merger After Ad Giants Pledge Not to Boycott Over Politics

FTC Approves Omnicom-IPG Merger After Ad Giants Pledge Not to Boycott Over Politics

Advertising holding company Omnicom Group can proceed with its proposed acquisition of rival Interpublic Group after the companies promised not to collude on politically motivated ad boycotts, the Federal Trade Commission said.
Omnicom, which owns agencies including BBDO and TBWA, in December agreed to buy IPG, whose portfolio includes McCann Worldgroup, in a transaction that would create the world's largest advertising company. The all-stock deal values IPG at around $13 billion and will create a conglomerate with approximately $25 billion in net revenue, based on 2024 figures for each company.
Executives at Omnicom and IPG had expressed confidence that the government would approve their plan, calling the incoming Trump administration more business-friendly. However, the FTC in March requested additional information from Omnicom and IPG, signaling a review of the deal.
The commission has also been investigating whether advertising holding companies and left-leaning advocacy groups broke antitrust laws by steering ad spending away from platforms such as Elon Musk's X.
In the agreement announced Monday, the companies pledged not to collude with other firms to move advertising dollars away from media outlets based on their perceived political or ideological alignment. The agreement doesn't include any admission of violations by Omnicom or IPG.
'Today's decision and order eliminates the potential for costly litigation while ensuring that Omnicom and IPG abide by the antitrust laws postmerger,' FTC Chairman Andrew N. Ferguson said in a statement. 'Moreover, this agreement requires Omnicom and IPG to cooperate with the commission in any investigation relating to media-buying services—and I have already noted that investigating and policing censorship practices that run afoul of the antitrust laws is a top priority of the Trump-Vance FTC.'
Omnicom also agreed not to develop so-called exclusion lists of sites or platforms where it doesn't recommend advertising, and said it would submit an annual report for the next five years demonstrating its compliance with the agreement.
'This is an important step toward the completion of the proposed acquisition and creating a new era in which we help clients grow with a comprehensive range of marketing and sales solutions, incorporating both creativity and technology,' John Wren, chief executive of Omnicom, said in a statement.
The FTC's approval is technically provisional, subject to 30 days of public comment and a final vote from the commission. The agreement, when final, will also release Omnicom and IPG from demands for information the commission made this month as part of its probe into alleged politically motivated ad boycotts against sites like X.
Other disputes over advertising and ideology continue. After a significant pullback in advertising on X, formerly known as Twitter, the social-media company sued both marketers and watchdog organizations such as Media Matters for allegedly colluding in an illegal ad boycott. X has threatened to drag more advertisers into court if they don't increase their spending on its platform, The Wall Street Journal reported this month.
Media Matters on Monday sued the FTC, arguing that the commission was trying to silence the group on behalf of Musk.
'This is a significant free speech issue, and Media Matters will not back down from this fight,' Chairman and President Angelo Carusone said in a statement.
And probes of the Omnicom-IPG merger remain open elsewhere. Regulatory agencies in the U.K. and Australia have each opened the deal to public comment to determine whether it would violate existing laws by creating an uneven playing field among companies that offer advertising- and media-buying services.
Omnicom and IPG have said that they expect the deal to close during the second half of this year.
Write to Patrick Coffee at patrick.coffee@wsj.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sibanye Stillwater Limited (SBSW): A Bull Case Theory
Sibanye Stillwater Limited (SBSW): A Bull Case Theory

Yahoo

time4 minutes ago

  • Yahoo

Sibanye Stillwater Limited (SBSW): A Bull Case Theory

We came across a bullish thesis on Sibanye Stillwater Limited on by walter99. In this article, we will summarize the bulls' thesis on SBSW. Sibanye Stillwater Limited's share was trading at $9.24 as of July 25th. SBSW's trailing and forward P/E were 4.67 and 10.94, respectively according to Yahoo Finance. A mine entrance, showcasing the precious metals and minerals that this company produces. Sibanye-Stillwater (SBSW), a major producer of platinum group metals (PGMs)—platinum, palladium, and rhodium—offers a leveraged play on a sector where years of underinvestment and misjudged demand forecasts have created the setup for an extended upcycle. PGMs are essential for automotive catalysts and jewelry, with catalytic converters alone accounting for 43% of platinum and 84% of palladium demand. Market pessimism has been fueled by overestimates of battery electric vehicle (BEV) penetration, but BEV sales growth in the U.S. and Europe flatlined in 2024, suggesting that internal combustion engine and hybrid vehicle demand—and thus PGM demand—will remain resilient. Supply is structurally constrained: South African PGM miners underspent by ~$18 billion over the last decade, 40% of global supply operates at or below cash costs, and production is forecast to decline through 2029. With long lead times for new supply, a persistent deficit projected by the World Platinum Investment Council, and palladium in deficit until at least 2028, any uptick in demand can drive a sharp price response. Recycling, a secondary supply source, remains depressed post-COVID, adding to market tightness. SBSW's profits, crushed by low PGM prices in 2024, have substantial torque to higher prices, as shown in 2020–2021 when the stock hit $20 on elevated metal prices. Today, at $7, platinum's rebound to $1,250 suggests early signs of a cyclical turn. Risks include economic weakness, faster BEV adoption, and rising recycling supply, but with constrained production, a decade of underinvestment, and platinum already rallying, SBSW presents asymmetric upside if PGM prices sustain an upcycle. Previously, we covered a on Sibanye Stillwater Limited (SBSW) by Hugo Navarro in February 2025, highlighting its diversified asset base in PGMs, gold, lithium, and recycling, with growth levers despite weak PGM prices. The stock has appreciated by about 130% as PGM prices rebounded. The thesis still stands, and Walter99 shares a similar view but emphasizes SBSW's leverage to a sustained PGM upcycle. Sibanye Stillwater Limited is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 20 hedge fund portfolios held SBSW at the end of the first quarter which was 18 in the previous quarter. While we acknowledge the potential of SBSW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures

Yahoo

time4 minutes ago

  • Yahoo

Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures and generalized epilepsy. The stock initially surged on the news, but then reversed course and is currently trading down approximately 9%. The central nervous system (CNS) disorders-focused company said the topline results from the Phase 2 RADIANT study included data from 37 patients.'These findings build on our earlier clinical data showing a differentiated profile for vormatrigine as a fast-acting, no-titration, once-daily oral drug with no requirement to be taken with food, and a favorable DDI profile, all of which are unseen in ASMs currently in the market or in development,' said Marcio Souza, president and CEO of Praxis. In an investor presentation on the company website, Praxis noted that the trial showed a median seizure reduction of around 56.3%, with 60% of the patients achieving at least a 50% reduction in seizures. This positive outcome has encouraged the company to move forward with a Phase 2/3 trial, even though 23% of patients discontinued the study. 54% of patients achieved at least a 50% seizure reduction threshold in Week 1 and 67% in Week 8. In the last month of the dataset, 22% of the patients experienced a 100% reduction in seizure frequency. The company added that most adverse events were mild to moderate and transient. All severe and serious adverse events (AEs) were recovered and resolved. The investor presentation noted that the investigators had the option to reduce the dose of the background medication to manage AEs; when done (6 patients), no discontinuation was observed. The company said it is on track to complete the pivotal, 12-week POWER1 study in the fourth quarter of 2025 and, based on the results from RADIANT, it expects to initiate the POWER2 study shortly. On Monday, the company reported cash and investments of approximately $447 million and maintains a cash runway into 2028. In July, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Praxis Precision's relutrigine, a sodium channel functional state modulator for pediatric use for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The EMBOLD cohort 2 pivotal trial is on track for topline results in the first half of 2026, with NDA filing to follow. Praxis has recently initiated the EMERALD study investigating relutrigine broadly in DEEs. Price Action: PRAX stock is trading lower by 9.51% to $48.95 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

Why Berkshire Hathaway may face 'pressure' to pay cash dividend
Why Berkshire Hathaway may face 'pressure' to pay cash dividend

Yahoo

time4 minutes ago

  • Yahoo

Why Berkshire Hathaway may face 'pressure' to pay cash dividend

Berkshire Hathaway (BRK-B, BRK-A) faces fresh scrutiny as Greg Abel prepares to take the reins from CEO Warren Buffett next year. Cathy Seifert, CFRA Research vice president of equity research, joins Opening Bid to discuss why investors may start pushing for a cash dividend and more clarity on leadership. To watch more expert insights and analysis on the latest market action, check out more Opening Bid. And Kathy, um, you know, we're of course approaching Greg Abel taking over at the beginning of next year. Um, will investors sort of give less of a pass to this company without Warren Buffett directly at the helm? I think that's a really good question and one of the things I think that investors are probably focused on and probably need to think about is that my sense is there may be pressure once Greg takes over for Berkshire to pay a cash dividend. They're one of the few components in the S&P 500, particularly given their size and their financial strength to not pay a cash dividend. And I think that's one thing investors may want to focus on in a new management um era at Berkshire. And I think the other thing investors are also focused on is that and and why the stock has underperformed, is that you have arguably one of the world's greatest investors stepping down from the helm of a very large conglomerate. The person um taking over has a very solid industrial background, but does not have a professional money management background. And we really haven't heard a lot of detail about some of the kind of um, I guess second tier management um strength at Berkshire. It's there. I think they would do investors and themselves a favor to highlight it, but we really haven't heard a lot of that. So there's, you know, there's a transition period in the broader economy that impacts Berkshire. There's also a transition at Berkshire that's impacting them and you know, more information is better than less. And unfortunately, we haven't heard a lot of details about the transition. Related Videos Musk's $29B award, Figma nosedives, OpenAI nears 700M users Elon Musk's $29B award may raise board independence concerns Wilbur Ross–backed BPGC taking iRocket public via $400M SPAC Tesla needs Elon Musk: Why investors awarded Musk $29B in stock Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store